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Abstract
Introduction: Bronchial asthma is an increasing problem worldwide. The course of bronchial asthma is dependent on the type 
of inducing allergens. The differences between the clinical features of asthma in patients with monovalent allergies to molds and 
with other allergies were explored.
Material and methods: Randomly selected 1910 patients (924 women and 986 men) between 18−86 years in age were 
analyzed according to type of allergy and asthma. The diagnosis of asthma was confirmed on the basis of GINA criteria, physical 
examination and spirometry. Allergy diagnosis was confirmed on the basis of medical history, a positive skin prick test and the 
measurement of serum-specific IgE to inhalant allergens, using an extended profile of mold allergens.
Results: Patients with monovalent allergies to molds (4% of analyzed group) had significantly more frequent diagnoses of asthma 
than patients in the other group (53% vs. 27.1−32.4%, p < 0.05). Patients with allergies to Alternaria alternata had an odds ratio 
of 2.11 (95%CI: 1.86−2.32) for receiving a diagnosis of bronchial asthma. They had less control over their asthma, which was 
more severe compared to patients with other allergies. Patients with asthma and allergies to mold had significantly more frequent 
exacerbation of asthma requiring systemic corticosteroids and/or hospitalization. They used a significantly greater mean daily 
dose of inhaled steroids compared to other patients.
Conclusion: Patients with monovalent IgE allergies to molds are at a higher risk for asthma than patients with other allergies. 
Their asthma is often more intense and less controlled compared to that of patients with other types of allergies.
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Introduction
Bronchial asthma is an increasing problem in 
all age groups. According to the WHO, between 
100 and 150 million people around the world suf-
fer from asthma, and this number is rising. World-
wide, deaths from this condition have reached 
over 180,000 annually [1]. There are a number of 
documents relating to the diagnosis and treatment 
of bronchial asthma, but our knowledge is incom-
plete in some fields [2−4]. The natural course of 
asthma is dependent on many factors, such as 
the type of inducing allergens. The majority of 
the available literature is devoted to mites, pollen 
and professional allergens, while less attention 
has been paid to animal (except cats) or mold 
allergens. Molds are extensive source of allergens. 
Exposure and sensitization to fungal allergens 
can promote the development and worsening of 
allergic diseases. Although numerous species of 
fungi have been associated with allergic diseases 
in the literature, the significance of fungi from the 
genera Alternaria, Cladosporium, Penicillium, and 
Aspergillus has been well documented [5].
The clinical spectrum of hypersensitivity 
reactions elicited by molds is very broad; in ad-
dition to IgE-mediated type I allergies, it includes 
type II, III and IV reactions, which are defined 
according to the criteria proposed by Coombs and 
Gell [6]. Clinically, IgE-mediated sensitization to 
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mold allergens can manifest as allergic rhinitis 
and rhinosinusitis, atopic dermatitis and allergic 
asthma [6].
Some information has been published regar-
ding the differences in the nature of asthma in 
patients with allergies to molds [6, 7]. However, 
we still lack detailed information on this issue. 
Additionally, the precise prevalence of fungal 
sensitivities remains unclear.
The aim of this study was to attempt to assess 
the differences between the clinical features of 
asthma in patients with monovalent allergies to 
molds and those with other allergies. This could 
be the starting point to draw attention to the 
special needs of these patients.
Material and methods
Patients
32 654 patients from Outpatient Allergo-
logical Clinics were prescreened in data bases. 
1910 subjects: 924 women and 986 men between 
18−86 years were randomly selected. They were 
analyzed according to their types of allergy and 
asthma.
The diagnosis of asthma was based on GINA 
criteria [2], physical examination and spirometry 
with a positive result on the reversibility test 
(Lung test 1000). A positive test result was defined 
in accordance with the criteria of the ATS-ERS 
[8, 9]. Before testing, the patients did not use 
short-acting beta2 agonists for 8 hours, ipratro-
pium derivatives or theophylline derivatives for 
24 hours, long-acting beta2 agonists for 48 hours, 
and tiotropium derivatives for 72 hours. Smokers 
were asked to abstain from smoking for 1 hour 
before testing. The test was deferred for 4 weeks 
in cases of respiratory tract infections.
The allergy diagnosis was confirmed on the 
basis of history, positive skin prick tests (SPT) and 
measurements of concentrations of serum-speci-
fic IgE (sIgE) in response to inhalant allergens. 
SPT (Allergopharma, Germany) was perfor-
med using the following allergens: D. pteronyssi-
nus, D. farinae, mixed grass, mixed tree, birch, 
alder, hazel, mugwort, and the molds Aspergillus 
fumigatus, Cladosporium herbarum, Botrytis cine-
rea, Alternaria alternata, Curvularia lunata, Peni-
cillium notatum, Fusarium moniliforme, Helmin-
thosporium solani, Mucor mucedo, Trichophyton 
mentagrophytes, Rhizopus nigricans, Pullularia 
pullulans, Neurospora sitophila, Candida albi-
cans, and Serpula lacrymans. Positive (histamine 
10 mg/ml) and negative (a saline control) tests 
were included. Allergy was defined as having a 
positive skin test result for at least one allergen 
with a wheal max. diameter of at least 3 mm 
greater than that of the negative control. Patients 
with negative tests for histamine were excluded 
from further analyses. 
The response of serum immunoglobulin le-
vels (serum sIgE) to all mentioned allergens were 
measured using the Phadia Laboratory System 
(Phadia AB, Uppsala, Sweden), an immunoenzy-
matic test. The results were assessed as positive 
when the serum sIgE concentration was > 0.75 
IU/ml (class II according to the manufacturer’s 
brochure) [10]. After the initial analysis, 1475 
patients with allergies and/or asthma were clas-
sified into four groups:
— Patients with monovalent allergies to molds, 
group M.
— Patients with monovalent allergies to house 
dust mites, group D.
— Patients with monovalent allergies to pollens 
(grass and/or trees and/or mugwort), group P. 
— Patients with multivalent allergies (allergies to 
at least two groups of allergies, including house 
dust mites, molds, and pollens), group V.
The monovalent allergy was confirmed as fol-
lowed: typical clinical symptoms (positive result 
of original questionnaire), positive skin prick test 
and/or allergen specific IgE to any allergen mold 
and negative results to other analyzed, inhalant 
allergens. Other monovalent allergies were dia-
gnosed in a similar way.
The characteristics of the groups are shown 
in Table 1.
Study protocol
Each subject completed the Asthma Control 
Test (ATC) [11] and an original questionnaire 
about mold allergies (Table 2). 
The study was approved by the local ethics 
committee (Medical University of Silesia, Kato-
wice, Poland). All patients signed an informed 
consent form.
Statistical analysis
Data with a normal distribution, such as 
participant age, disease duration and spirome-
tric test results were compared using Student’s 
t-test for independent samples. Odds ratios were 
calculated to assess the likelihood of asthma in 
the presence of a particular trait in the subjects. 
Kruskal-Wallis test was used to compare non-pa-
rametric variables between the groups. P < 0.05 
was considered statistically significant.
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Table 1. Characteristics of the study groups
Patients included in the analysis, n = 1475 
Features group M
n = 64
group D
n = 383
group P
n = 388
group V
n = 415
Mean age 38.1 ± 19.1 43.2 ± 10.5 36.7 ± 11.9 34.8 ± 10.3
Female (%) 43.1 38.5 37.8 40.2
Duration of allergy in years (± SD) 8.2 ± 3.7 6.9 ± 1.4 6.8 ± 6.2 6.2 ± 4.9
Residence: village 22.1% 21.7% 22.5% 22.3%
Smoking (current or former) 27.4% 34.8% 39.7% 33.1%
Higher education 25.6% 22.1% 24.7% 18.7%
Allergy in the family 33.4% 35.1% 40.1% 38.9%
Allergy in childhood 35.9% 33.7% 29.7% 52.6%*
SD — standard deviation; group M — monovalent allergy to molds; group D — monovalent allergy to house dust mites; group P — monovalent allergy to pollens; 
group V — multivalent allergy; *significant differences for p < 0.05
Table 2. Original questionnaire about allergies to fungi
Do your disease symptoms, such as runny nose, cough, shortness of breath, and watery or itchy eyes, occur in the period 
from June to August and/or in the autumn and winter months?  
YES or NO
Are your symptoms associated with being in humid areas, such as basements, old houses and other premises, where mold is 
visible on the wall?  
YES or NO
Do similar symptoms as listed in paragraph 1 arise when you stay in a steamy bathroom?  YES or NO
Do similar symptoms occur during sleep in your bed? YES or NO
Do you live in a home where there is visible mold on the walls?  YES or NO
Do you have allergic symptoms (at least one of the following symptoms: rash, cough, shortness of breath, runny nose, abdo-
minal pain, or diarrhea) after eating any of these foods: yeast dough, moldy cheeses, red wine, or pickled preserves?  
YES or NO
Have you ever had a confirmed allergic skin test or blood test IgE sensitization to mold fungi?  YES or NO
Do you have asthma-like symptoms (coughing or difficulty in breathing) that require treatment in the summer?  YES or NO
Do you suffer from bronchial asthma and are using drugs?  YES or NO
Does anyone in your family have a known allergy to molds?  YES or NO
Does the presence of a large number of potted plants have an effect on your disease symptoms?  YES or NO
Do you badly tolerate staying in air-conditioned rooms or in the car with the air conditioner? YES or NO
Results
Patients with monovalent allergy to molds 
represented 4.3% of all respondents with inha-
lant allergy. The original questionnaire about 
mold allergies indicated the special importance 
of patient exposure to damp basements (89% of 
the patients with allergies to mold answered YES 
to the second question and the questions about 
steamy bathrooms; 86% of respondents answered 
YES to the third question) in describing the symp-
toms of allergies to mold fungi. The questionnaire 
results from the control groups without allergies 
to molds were significantly negative in relation to 
the study group for all of the targeted questions.
Patients with monovalent allergies to mold 
had significantly more diagnoses of asthma than 
the patients in the other analyzed groups: 53% 
(34 subjects) vs. 32.4% (124) in group D vs. 27.1% 
(105) in group P and vs. 29.2% (121) in group V 
(p < 0.05). There were no correlation between 
diagnosis of asthma and age or sex in all analyzed 
groups.
IgE-specific skin prick tests 
In the group of patients monosensitized to 
molds, allergies to the following species domi-
nated: Alternaria alternata in 57.2% of patients 
(based on a positive SPT and/or sIgE), Cladospo-
rium herbarum in 40.9% of patients, Aspergillus 
fumigatus in 34.7% of patients, Mucor mucedo in 
30.1% of patients, Trichophyton mentagrophytes 
in 21.2% of patients and Fusarium moniliforme 
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Table 3. Profile of mold allergies in group M (% of patients) according to asthma severity
Allergy to mold species Episodic asthma Mild or moderate
asthma
Severe asthma p
Alternaria alternata 17.1 20.8 22.1 NS
Cladosporium herbarum 10.1 14.2 11.5 NS
Aspergillus fumigatus 6.9 9.2 18.1 > 0.05
Mucor mucedo 8.8 11.9 10.2 NS
Trichophyton mentagrophytes 2.7 7.3 16.1 > 0.05
Fusarium moniliforme 5.6 4.9 5.5 NS
Other species 1.1 0.8 0.7 NS
NS — no significant differences
Table 4. Characteristics of bronchial asthma in patients with different types of allergies
Characteristics Patients with asthma diagnoses P^
group M
n = 32 (%)
group D
n = 124 (%)
group P
n = 105 (%)
group V
n = 121 (%)
Mean age 42.9 ± 10.4 44.1 ± 13.9 42.1 ± 10.2 39.5 ± 8.9 NS
Female (%) 16 (47.1) 60 (48.4) 45 (42.9) 53 (43.8) NS
Duration of asthma 10.4 ± 5.2 9.2 ± 5.1 9.7 ± 3.6 9.3 ± 6.3 NS
Mean result of ACT 11.9 ± 3.1* 15.9 ± 4.8 19.7 ± 3.7 18.5 ± 7.4 < 0.05
Severe asthma (%) 8 (26.5)* 18 (14.5) 11 (10.5) 15 (12.4) < 0.05
Moderate asthma (%) 9 (26.8) 35 (28.2) 30 (24.2) 32 (26.4) NS
Mild asthma (%) 12 (35.3) 43 (34.7) 39 (37.2) 47 (38.8) NS
Episodic asthma (%) 5 (14.7)* 28 (22.5) 25 (23.8) 27 (22.3) < 0.05
Fully control asthma 11 (32.4)* 58 (46.8) 49 (46.7) 54 (44.6) < 0.01
Partially controlled asthma 10 (29.4) 32 (25.8) 35 (33.3) 36 (29.8) NS
Uncontrolled asthma 13 (29.4)* 34 (27.4) 21 (20) 31 (25.6) < 0.01
Allergic rhinitis 30 (88.2) 108 (87.1) 97 (92.4) 107 (88.4) NS
Degree of asthma control according to the GINA; ACT — asthma control test; *Significant difference for p < 0.05
in 19.1% of patients. Other allergens occurred in 
less than 20% of the patients. 
In group M, patients with diagnoses of va-
rying degrees of bronchial asthma had similar 
profiles to those with mold allergies. However, 
patients with allergies to Aspergillus fumigatus 
and Trichophyton mentagrophytes were signifi-
cantly more likely to suffer from severe asthma. 
The detailed results are shown in Table 3.
Additionally, patients with an allergy to 
Alternaria alternata had an odds ratio of 2.11 
(95%CI: 1.86−2.32) of receiving a diagnosis of 
bronchial asthma.
Furthermore, they had less control over their 
asthma, which was more severe compared to that 
of patients with other allergies (Table 4). Patients 
with both asthma and allergies to mold had si-
gnificantly more exacerbated asthma requiring 
systemic corticosteroids and/or hospitalization. 
The results are shown in Figure 1. 
Patients with both asthma and allergies to 
mold used a significantly greater mean daily dose 
of inhaled steroids compared to patients with 
other types of allergies and asthma; the use of 
fluticasone propionate in the groups was 730 ± 
425* mcg vs. 430 ± 225 mcg vs. 470 ± 165 mcg 
vs. 340 ± 140 mcg (p < 0.05).
 Discussion
The obtained results indicate the important 
problem of bronchial asthma in patients with al-
lergies to mold. Of the analyzed allergic patients, 
those with monovalent allergies to mold had 
Krzysztof Kołodziejczyk et al., The clinical differences of asthma in patients with molds allergy
85www.pneumonologia.viamedica.pl
9
8
7
6
5
4
3
2
1
0
Exacerbation:
mean days per
7,8*
5,2
5,9
3
4*
2,5 2,7
3,5
Hospitalization:
mean days per
Year
Group M
Group D
Group P
Group V
Figure 1. The number of asthma exacerbations per year and hospitalizations caused by asthma in the study groups
significantly more frequent diagnoses of asthma. 
In this group, patients with allergies to Alterna-
ria were predominant. This finding is consistent 
with previous observations. Alternaria is a major 
environmental allergen associated with asthma 
and allergic rhinitis [12, 13]. Alternaria spp. are 
generally considered to be outdoor fungi, altho-
ugh they also exist in indoor environments [5, 14]. 
Airborne outdoor Alternaria spores are detectable 
from May to November, with the highest levels 
occurring in cultivated areas containing grass-
lands and grain [14]. The clinical significance 
of A. alternata as a respiratory allergen has been 
well documented. Studies have revealed a strong 
association between sensitization to Alternaria 
spp. and the presence of asthma or allergic rhi-
nitis, as well as the severity of asthma [5, 15, 
16]. In addition, sensitization and exposure to 
Alternaria has been associated with epidemics of 
severe asthma exacerbation, including respiratory 
arrest [17]. Thunderstorms appear to be a contri-
buting factor to high levels of fungal spores and 
epidemics of asthma exacerbation [5]. 
We found that sensitivities to two molds, 
Aspergillus fumigatus and Trichophyton men-
tagrophytes, were more common in patients 
with severe asthma than in others. Aspergillus, 
Penicillium, Alternaria and Cladosporium, play 
important roles in the induction of asthma as 
well as in its intensity patterns [6, 7]. Aspergillus 
fumigatus can cause allergic bronchopulmo-
nary aspergillosis, which is characterized by 
its exacerbation of asthma, recurrent transient 
infiltrates on radiographic images, coughing up 
of thick mucus plugs, peripheral and pulmonary 
eosinophilia, and increased total serum IgE and 
specific IgE levels, especially during exacerba-
tion [18]. In this study, five patients with bron-
chial asthma, allergy to molds and episode of 
bronchopulmonary aspergillosis were observed. 
The importance of Trichophyton mentagrophytes 
had not been previously confirmed. Fungi in the 
genus Trichophyton are known to be the causal 
pathogens of dermatophytosis, a fungal infection 
of the skin, hair and nails. Trichophyton rubrum 
and Trichophyton mentagrophytes are the most 
common pathogens in the genus [5]. However, 
the route of exposure to Trichophyton allergens 
in such Trichophyton-infected patients has not 
been identified. A few reports have suggested the 
possible role of inhaled Trichophyton in the path-
ogenesis of asthma or rhinoconjunctivitis among 
subjects without Trichophyton infections [19, 20]. 
Occupational exposure to airborne Trichophyton in 
nail dust has been shown to induce nasal and eye 
symptoms in chiropodists [21]. There was no such 
data in our study. Sensitization to Trichophyton is 
also reported to be a risk factor for more severe 
disease among the general asthmatic population 
[22, 23]. However, there is no published infor-
mation regarding whether a potential correlation 
exists between Trichophyton and asthma severity.
 An important limitation of this study is our 
testing of IgE-dependent responses only. There is 
group M — monovalent allergy to molds; group D — monovalent allergy to house dust mites; group P — monovalent allergy to 
pollens; group V — multivalent allergy; *significant differences for p < 0.05
Pneumonologia i Alergologia Polska 2016, vol. 84, no. 2, pages 81–86 
86 www.pneumonologia.viamedica.pl
evidence that these species of molds also induce 
type II, III and IV reactions [6]. Thus, the obtained 
results about the roles of different types of molds 
on asthma are not final.
Worse asthma control, a greater number of 
exacerbations and the need for larger doses of 
inhaled steroids are the results of the higher 
prevalence of severe asthma that was observed 
in this study. The important role of fungi in the 
exacerbation of asthma has been confirmed in 
previous literature. TNF-alpha as well as IFN-al-
pha are secreted by fungi-prestimulated leuko-
cytes from the lower respiratory tract and may 
be involved in the processes of exacerbation of 
asthma complicated by fungal infections [24]. 
However, further details on this role have not 
been provided [2, 6, 12, 16].
Conclusion
The obtained data suggest that patients with 
monovalent IgE allergies to mold are more at risk 
for asthma than patients with other allergies. The-
se patients require more attention because their 
asthma is often more severe and less controlled 
than that of patients with other types of allergies.
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